{
  "id": "1325504171d5ac19",
  "title": "Reframing Fibromyalgia Care in 2025 : Restricted Impact of TNX - 102 SL Approval",
  "description": "20251230T183000Z",
  "content": "",
  "source": "hcplive.com",
  "source_url": "https://www.hcplive.com/view/reframing-fibromyalgia-care-2025-restricted-impact-tnx-102-sl-approval",
  "published_at": "20251230T183000Z",
  "fetched_at": "2025-12-31T00:23:34.453563+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.hcplive.com/view/reframing-fibromyalgia-care-2025-restricted-impact-tnx-102-sl-approval",
    "url_mobile": "",
    "title": "Reframing Fibromyalgia Care in 2025 : Restricted Impact of TNX - 102 SL Approval",
    "seendate": "20251230T183000Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/hcplive/b142a7e128c5065d44aeea38d3fadf5a602699c5-858x480.png",
    "domain": "hcplive.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}